Epithalon and Carbohydrate Metabolism

Epithalon is usually associated with telomeres and 'anti-aging', but its developers' literature contains a separate line of inquiry as well — its effect on the hormonal functions of the pineal gland and pancreas. Our editorial team examines how the circadian system is linked to carbohydrate metabolism, what studies of Epithalon reported, and why it is still too early to draw practical conclusions.

The pineal gland, melatonin and glucose

The pineal gland produces melatonin mainly during the dark hours, and this hormone serves as the body's 'night' signal. It synchronizes the peripheral 'clocks' in the liver, muscles, adipose tissue and pancreas. The review by Cipolla-Neto and colleagues (2014) describes melatonin's role in energy metabolism in detail.

The beta cells of the pancreas have melatonin receptors, and the hormone influences insulin secretion. Important genetic data appeared in 2009: two independent groups in the journal Nature Genetics (Bouatia-Naji et al.; Lyssenko et al.) showed that a common variant of the melatonin receptor gene MTNR1B is associated with higher fasting glucose and an increased risk of type 2 diabetes.

The circadian rhythm also affects glucose tolerance over the course of the day: in most people the same meal eaten in the evening or at night causes a higher glucose rise than in the morning. Disruption of the rhythm — shift work, nighttime snacking, chronic sleep deprivation — worsens carbohydrate metabolism.

Scheer and colleagues (2009) experimentally showed that misalignment of the circadian rhythm with sleep and eating schedules in humans leads to elevated post-meal glucose, reaching prediabetic levels in some participants. Thus, the link between the 'internal clock' and glucose is quite real.

What was reported about Epithalon

The main data on Epithalon's effect on metabolism come from studies in old rhesus macaques conducted by Khavinson's group together with primatologists. Khavinson, Goncharova and Lapin (2001) reported that the synthetic tetrapeptide restored the age-impaired evening secretion of melatonin in old monkeys.

In subsequent work by Goncharova and colleagues (2005) in the journal Experimental Gerontology, pineal peptides, according to the authors, corrected age-related impairments not only of pineal function but also of the pancreas: improvements in glucose and insulin measures during a glucose tolerance test were described in old animals.

The authors interpreted this as a consequence of 'normalization of neuroendocrine regulation': if the circadian melatonin signal is restored, then the pancreas also receives the correct temporal signals. The idea is logical but requires direct verification.

Also, in rodent studies related to the investigation of lifespan, Anisimov's group mentioned favorable changes in metabolic biomarkers of aging. However, these data did not focus on carbohydrate metabolism and do not allow specific conclusions to be drawn.

Why 'more melatonin' is not always better

The popular logic 'Epithalon raises melatonin → melatonin improves metabolism' oversimplifies complex physiology. Melatonin's effect on glucose depends on timing: a high hormone level during a meal can worsen glucose tolerance, especially in carriers of the risk variant of the MTNR1B gene.

The review by Garaulet and colleagues (2020) is devoted precisely to this contradiction: melatonin at the right time probably supports normal metabolism, but its action combined with a late dinner may be unfavorable. That is, what matters is not only the level but also the alignment of melatonin with the eating schedule.

Hence a practical conclusion: even if Epithalon really did enhance evening melatonin secretion in humans, the result for carbohydrate metabolism would depend on lifestyle — dinner timing, sleep duration, genetics.

• Melatonin is a night signal, not a 'metabolic stimulant'.
• Combining high melatonin with a late meal can worsen glycemia.
• MTNR1B genetic variants alter sensitivity to this effect.
• Sleep and eating schedules matter more than any single substance.

Gaps in the evidence

The most important gap is the absence of randomized placebo-controlled studies of Epithalon in humans assessing carbohydrate metabolism. There are no data on fasting glucose, glycated hemoglobin or insulin resistance under controlled conditions.

The monkey studies had a small number of animals and were conducted by the same scientific school that developed the peptide. The editorial team found no independent replications in the available literature.

The mechanism of Epithalon's action on the pineal gland is also unclear. The hypothesis of direct gene regulation by short peptides is not generally accepted, and so the chain 'peptide — pineal gland — pancreas' remains an assumption.

Finally, there are no data on the interaction of Epithalon with glucose-lowering drugs. For people with diabetes this means that any changes in glycemia while taking the peptide would be unpredictable.

What actually works for carbohydrate metabolism

If the goal is to improve insulin sensitivity, there are interventions with a convincing evidence base. Regular physical activity, including strength training, increases glucose uptake by muscles. Reducing excess body weight by even a few percent noticeably improves the measures.

Sleep and eating schedules are an area where circadian science gives direct advice: adequate sleep duration, a stable schedule, the bulk of calories in the first half of the day, and no late heavy dinners.

For people with prediabetes or diabetes, treatment standards, in particular the Standards of Care of the American Diabetes Association, also define pharmacological approaches that a doctor selects based on test results.

Laboratory monitoring — fasting glucose, HbA1c and, if needed, a glucose tolerance test — allows the result of any changes to be assessed objectively rather than relying on how one feels.

Editorial conclusions

The circadian system and melatonin are indeed linked to carbohydrate metabolism, as confirmed by genetic and experimental studies in humans.

The data suggesting that Epithalon improves pancreatic function are limited to small studies in old monkeys from a single research group.

Melatonin's effect on glucose depends on timing and lifestyle, so a hypothetical 'increase in melatonin' is no guarantee of metabolic benefit.

We also recommend reading 'AOD-9604 and Carbohydrate Metabolism', 'Epithalon and Cancer Risks: What Studies Say' and 'AOD-9604 and Sleep'.

References

1. Khavinson V, Goncharova N, Lapin B. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001;22(4):251–254.
2. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Exp Gerontol. 2005;40(1-2):51–57.
3. Cipolla-Neto J, Amaral FG, Afeche SC, et al. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56(4):371–381.
4. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.
5. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–88.
6. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106(11):4453–4458.
7. Garaulet M, Qian J, Florez JC, et al. Melatonin effects on glucose metabolism: time to unlock the controversy. Trends Endocrinol Metab. 2020;31(3):192–204.
8. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1).